Isoflavonoid compositions and methods for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-11723893-B2
Application number	US-202117193335-A
Country	US
Kind code	B2
Filing date	Mar 5, 2021
Priority date	Nov 1, 2010
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

First claim

What is claimed is:

1. A pharmaceutical composition comprising: i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 90% enantiomeric excess and ii) a cyclodextrin.

2. The pharmaceutical composition of claim 1 , wherein the cyclodextrin is selected from the group consisting of SAE-CD derivatives, SBE-α-CD, SBE-β-CD, SBE1-β-CD, SBE4-β-CD, SBE7-β-CD, SBE-γ-CD, hydroxypropyl-β-cyclodextrin, 2-HP-β-CD, hydroxyethyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, hydroxyethyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, glucosyl-α-cyclodextrin, glucosyl-β-cyclodextrin, diglucosyl-β-cyclodextrin, maltosyl-α-cyclodextrin, maltosyl-β-cyclodextrin, maltosyl-γ-cyclodextrin, maltotriosyl-β-cyclodextrin, maltotriosyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, methyl-β-cyclodextrin, and derivatives and/or combinations thereof.

3. The pharmaceutical composition of claim 1 , wherein the cyclodextrin is SBE7-β-CD.

4. The pharmaceutical composition of claim 1 , wherein the cyclodextrin has a concentration (w/v) ranging from about 0.001% to about 50%.

5. The pharmaceutical composition of claim 1 , wherein the composition further comprises water.

6. The pharmaceutical composition of claim 1 , wherein the composition further comprises one or more of lactose, dextrose, mannitol, a pH buffering agent, an antioxidant agent, a preservative agent, a tonicity adjuster, or a combination thereof.

7. The pharmaceutical composition of claim 1 , wherein the composition comprises d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol in an amount of about 0.2-50 mg/mL.

8. A method of treating cancer in an individual in need of cancer therapy, the method comprising administering to the individual a pharmaceutical composition comprising: —i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 90% enantiomeric excess and —ii) a cyclodextrin.

9. The method of claim 7 , wherein the pharmaceutical composition increases or induces sensitivity of the cancer to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

10. The method of claim 7 , wherein the cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

11. The method of claim 7 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, and cancers of the brain.

12. The method of claim 7 , wherein the cancer is human breast cancer or ovarian cancer.

Assignees

• Mei Pharma Inc

Inventors

• Moreno Ofir

Classifications

• A61K31/353 Primary

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/5161

  Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title